The US diabetes care drug market is projected to grow significantly during the forecast period. The primary factors driving the growth of the US diabetes care drugs industry include the rising prevalence of diabetes amongst the peoples across the US. According to International Diabetes Federation (IDF), the number of adults with diabetes in the US accounted for 31.0 million peoples in 2019, which is expected to increase up to 34.4 million peoples in 2030, which will further increase to 36.0 million peoples in 2045. The increased cases of diabetes will further create demand for drugs and hence provide growth opportunities to the market to grow in the near future. Further, the presence of the key players also supports the growth of the US diabetes care drugs market over the forecast period. 

The US diabetes care drugs market is segmented on the basis of drug class as insulins, non-insulin injectable drugs, oral anti-diabetic drugs, and combination drugs. Insulins are among the most consumed and favored drug, owing to their fast- and long-action properties. Hence, it is likely to support the US diabetes care drug market. Further, the availability of a wide range of insulin also enhances the segmental growth of the market over the forecast period.

Further, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., Merck & Co. Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., and Takeda Pharmaceuticals Industries Ltd. are some of the prominent global players operating in the North America diabetes care drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. For instance, in February 2020, Sun Pharmaceutical Industries through its wholly-owned subsidiary launched Riomet ER, used to treat type 2 diabetes mellitus, in the US market. Riomet ER is the first and only US FDA-approved liquid formulation of extended-release metformin

Research Methodology

The market study of the US diabetes care drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for diabetes care drug market players, drug manufacturing companies, investment companies, industry associations and experts, research institutes, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. US Diabetes Care Drugs Market Research and Analysis by Drug Class

The Report covers:

• Comprehensive research methodology of the US diabetes care drug market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the US diabetes care drug market.
• Insights about market determinants that are stimulating the US diabetes care drugs market.
• Detailed and extensive market segments with regional distribution of forecast revenues.
• Extensive profiles and recent developments of the market players.